To order Seprafilm or for more information, call 1-800-261-1570 Instructions for Use (IFU)
OPEN MOBILE NAV
For US Healthcare Professionals Only

IMPORTANT SAFETY INFORMATION

Seprafilm should not be wrapped around an intestinal anastomosis as such usage may result in increased anastomotic leak-related events, such as abscess or peritonitis. The safety and effectiveness of Seprafilm [...]  View Full Important Safety Information

For US Healthcare Professionals Only

Before the Risk of Adhesions MAY BECOME THE REALITY

Seprafilm significantly reduces the incidence, extent, and severity of adhesions following abdominopelvic surgery1,2

RISK OF ADHESIONS

Up to 93% of patients have been shown to develop adhesions following laparotomy.2


SEPRAFILM IN ACTION

Watch a video on how to use Seprafilm.


SEPRAFILM EFFICACY

In a pivotal trial, only 49% of Seprafilm patients developed adhesions versus 94% of untreated patients.2*

*Randomized, double-blinded, multicenter, clinical study involving 183 patients (175 evaluable) with ulcerative colitis and familial polyposis undergoing abdominal surgery.

References

  1. Seprafilm® Adhesion Barrier Instructions for Use (IFU); Genzyme Corporation, Cambridge, MA; 2012.
  2. Becker JM, Dayton MT, Fazio VW, et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg. 1996;183(4):297-306.

Ā©2002 - 2015 sanofi-aventis U.S. LLC, A SANOFI COMPANY
Privacy Policy   |  Legal Disclaimer